103 related articles for article (PubMed ID: 2814944)
1. Effects of Hydergine on platelet deposition on "active" human carotid artery lesions and platelet function.
Steurer G; Fitscha P; Ettl K; Sinzinger H
Thromb Res; 1989 Sep; 55(5):577-89. PubMed ID: 2814944
[TBL] [Abstract][Full Text] [Related]
2. Double blind study of the influence of co-dergocrine on platelet parameters in healthy volunteers.
Sinzinger H
Eur J Clin Pharmacol; 1985; 28(6):713-6. PubMed ID: 2998802
[TBL] [Abstract][Full Text] [Related]
3. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
[TBL] [Abstract][Full Text] [Related]
4. Influence of co-dergocrine on platelet aggregation.
Santos RO; Rodrigues R
Braz J Med Biol Res; 1990; 23(3-4):325-7. PubMed ID: 2094545
[TBL] [Abstract][Full Text] [Related]
5. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years.
Köberle S; Spiegel R
Gerontology; 1984; 30 Suppl 1():3-52. PubMed ID: 6489764
[TBL] [Abstract][Full Text] [Related]
6. Co-dergocrine (hydergine) in the treatment of tardive dyskinesia.
Rastogi SC; Blowers AJ; Gibson AC
Psychol Med; 1982 May; 12(2):427-9. PubMed ID: 6124989
[TBL] [Abstract][Full Text] [Related]
7. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.
von Hundelshausen P; Weber KS; Huo Y; Proudfoot AE; Nelson PJ; Ley K; Weber C
Circulation; 2001 Apr; 103(13):1772-7. PubMed ID: 11282909
[TBL] [Abstract][Full Text] [Related]
8. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
[TBL] [Abstract][Full Text] [Related]
9. The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine').
Kitamura S
Pharmatherapeutica; 1980; 2(5):330-6. PubMed ID: 7433473
[TBL] [Abstract][Full Text] [Related]
10. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography.
Nagasawa H; Kogure K; Kawashima K; Ido T; Itoh M; Hatazawa J
Tohoku J Exp Med; 1990 Nov; 162(3):225-33. PubMed ID: 2091324
[TBL] [Abstract][Full Text] [Related]
11. Effect of isradipine on in-vivo platelet function.
O'Grady J; Kritz H; Schmid P; Pirich C; Sinzinger H
Thromb Res; 1997 Jun; 86(5):363-71. PubMed ID: 9211627
[TBL] [Abstract][Full Text] [Related]
12. Effect of TRK-100, a stable orally active prostacyclin analogue, on platelet function and plaque size in atherothrombotic strokes.
Isaka Y; Handa N; Imaizumi M; Kimura K; Kamada T
Thromb Haemost; 1991 Apr; 65(4):344-50. PubMed ID: 2057914
[TBL] [Abstract][Full Text] [Related]
13. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model.
Cruz CP; Eidt J; Drouilhet J; Brown AT; Wang Y; Barnes CS; Moursi MM
J Vasc Surg; 2001 Oct; 34(4):724-9. PubMed ID: 11668330
[TBL] [Abstract][Full Text] [Related]
14. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques.
van Montfoort ML; Kuijpers MJ; Knaup VL; Bhanot S; Monia BP; Roelofs JJ; Heemskerk JW; Meijers JC
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1668-73. PubMed ID: 24947525
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of platelets with encapsulated iloprost to balloon injured pig carotid arteries: effect on platelet deposition and neointima formation.
Banning A; Brewer L; Wendt M; Groves PH; Cheadle H; Penny WJ; Crawford N
Thromb Haemost; 1997 Jan; 77(1):190-6. PubMed ID: 9031472
[TBL] [Abstract][Full Text] [Related]
16. The double-tuck model: a new animal model of arterial thrombosis.
Gomez-Jorge J; Becker GJ; Rodriguez MM; Halgowich J; Leone J
J Vasc Interv Radiol; 1998; 9(4):633-8. PubMed ID: 9684835
[TBL] [Abstract][Full Text] [Related]
17. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
[TBL] [Abstract][Full Text] [Related]
18. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation.
Massberg S; Brand K; Grüner S; Page S; Müller E; Müller I; Bergmeier W; Richter T; Lorenz M; Konrad I; Nieswandt B; Gawaz M
J Exp Med; 2002 Oct; 196(7):887-96. PubMed ID: 12370251
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
Huang J; Rebello SS; Faul JD; Lucchesi BR
Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
[TBL] [Abstract][Full Text] [Related]
20. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).
Byington RP; Furberg CD; Crouse JR; Espeland MA; Bond MG
Am J Cardiol; 1995 Sep; 76(9):54C-59C. PubMed ID: 7572688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
